Qlaris Bio Appoints Robert Warner to Board of Directors
Qlaris Bio, a clinical-stage biotech company developing therapies for glaucoma, appointed Robert Warner to its board of directors on January 27, 2026.367
Warner is an experienced life sciences executive with expertise in corporate strategy, financing, and leadership, including past role as President, North America at Alcon.3
The appointment supports Qlaris Bio's advancement of lead program QLS-111, a topical ATP-sensitive potassium channel modulator targeting episcleral venous pressure (EVP) in late-stage trials for glaucoma.35
CEO Thurein Htoo highlighted Warner's ophthalmology commercial leadership as key for QLS-111's next clinical phase.3
Warner expressed excitement to join amid Qlaris Bio's progress in glaucoma treatment innovation.3
Sources:
3. https://www.businesswire.com/news/home/20260127834116/en/Qlaris-Bio-Appoints-Robert-Warner-to-Board-of-Directors
5. https://qlaris.bio/about-us/